Cargando…
A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. A total of 601 patient...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809456/ https://www.ncbi.nlm.nih.gov/pubmed/33446902 http://dx.doi.org/10.1038/s41598-021-81019-8 |
_version_ | 1783637126760366080 |
---|---|
author | Du, Lingyao Ma, Yuanji Zhou, Shaoqun Chen, Fang Xu, Yan Wang, Ming Lei, Xuezhong Feng, Ping Tang, Hong Bai, Lang |
author_facet | Du, Lingyao Ma, Yuanji Zhou, Shaoqun Chen, Fang Xu, Yan Wang, Ming Lei, Xuezhong Feng, Ping Tang, Hong Bai, Lang |
author_sort | Du, Lingyao |
collection | PubMed |
description | Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. A total of 601 patients were retrospectively enrolled and randomly divided into a derivation cohort of 303 patients and a validation cohort of 298 patients for logistic regression analysis, respectively. Five baseline variables, including liver cirrhosis, total bilirubin, international normalized ratio of prothrombin time, infection and hepatic encephalopathy, were found independently associated with 3-month mortality. A predictive PALS model and the simplified PALS score were developed. The predicative value of PALS score (AUROC = 0.818) to 3-month prognosis was as capable as PALS model (AUROC = 0.839), R score (AUROC = 0.824) and Yue-Meng’ score (AUROC = 0.810) (all p > 0.05), and superior to CART model (AUROC = 0.760) and MELD score (AUROC = 0.765) (all p < 0.05). The PALS score had significant linear correlation with 3-month mortality (R(2) = 0.970, p = 0.000). PALS score of 0–2 had both sensitivity and negative predictive value of > 90% for 3-month mortality, while PALS score of 6–9 had both specificity and positive predictive value of > 90%. Patients with PALS score of 3–5 who received 3–5 sessions of ALSS therapy had much lower 3-month mortality than those who received 1–2 sessions (32.8% vs. 59.2%, p < 0.05). The more severe patients with PALS score of 6–9 could still benefit from ≥ 6 sessions of ALSS therapy compared to ≤ 2 sessions (63.6% vs. 97.0%, p < 0.05). The PALS score could predict prognosis reliably and conveniently. It could identify the subgroups who could benefit from PE-centered ALSS therapy, and suggest the reasonable sessions. Trial registration: Chinese Clinical Trial Registry, ChiCTR2000032055. Registered 19th April 2020, http://www.chictr.org.cn/showproj.aspx?proj=52471. |
format | Online Article Text |
id | pubmed-7809456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78094562021-01-21 A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system Du, Lingyao Ma, Yuanji Zhou, Shaoqun Chen, Fang Xu, Yan Wang, Ming Lei, Xuezhong Feng, Ping Tang, Hong Bai, Lang Sci Rep Article Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. A total of 601 patients were retrospectively enrolled and randomly divided into a derivation cohort of 303 patients and a validation cohort of 298 patients for logistic regression analysis, respectively. Five baseline variables, including liver cirrhosis, total bilirubin, international normalized ratio of prothrombin time, infection and hepatic encephalopathy, were found independently associated with 3-month mortality. A predictive PALS model and the simplified PALS score were developed. The predicative value of PALS score (AUROC = 0.818) to 3-month prognosis was as capable as PALS model (AUROC = 0.839), R score (AUROC = 0.824) and Yue-Meng’ score (AUROC = 0.810) (all p > 0.05), and superior to CART model (AUROC = 0.760) and MELD score (AUROC = 0.765) (all p < 0.05). The PALS score had significant linear correlation with 3-month mortality (R(2) = 0.970, p = 0.000). PALS score of 0–2 had both sensitivity and negative predictive value of > 90% for 3-month mortality, while PALS score of 6–9 had both specificity and positive predictive value of > 90%. Patients with PALS score of 3–5 who received 3–5 sessions of ALSS therapy had much lower 3-month mortality than those who received 1–2 sessions (32.8% vs. 59.2%, p < 0.05). The more severe patients with PALS score of 6–9 could still benefit from ≥ 6 sessions of ALSS therapy compared to ≤ 2 sessions (63.6% vs. 97.0%, p < 0.05). The PALS score could predict prognosis reliably and conveniently. It could identify the subgroups who could benefit from PE-centered ALSS therapy, and suggest the reasonable sessions. Trial registration: Chinese Clinical Trial Registry, ChiCTR2000032055. Registered 19th April 2020, http://www.chictr.org.cn/showproj.aspx?proj=52471. Nature Publishing Group UK 2021-01-14 /pmc/articles/PMC7809456/ /pubmed/33446902 http://dx.doi.org/10.1038/s41598-021-81019-8 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Du, Lingyao Ma, Yuanji Zhou, Shaoqun Chen, Fang Xu, Yan Wang, Ming Lei, Xuezhong Feng, Ping Tang, Hong Bai, Lang A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system |
title | A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system |
title_full | A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system |
title_fullStr | A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system |
title_full_unstemmed | A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system |
title_short | A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system |
title_sort | prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809456/ https://www.ncbi.nlm.nih.gov/pubmed/33446902 http://dx.doi.org/10.1038/s41598-021-81019-8 |
work_keys_str_mv | AT dulingyao aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT mayuanji aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT zhoushaoqun aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT chenfang aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT xuyan aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT wangming aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT leixuezhong aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT fengping aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT tanghong aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT bailang aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT dulingyao prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT mayuanji prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT zhoushaoqun prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT chenfang prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT xuyan prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT wangming prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT leixuezhong prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT fengping prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT tanghong prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem AT bailang prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem |